540596 Stock Overview Provides domestic branded formulations for chronic and sub-chronic therapies in India. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Eris Lifesciences Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Eris Lifesciences Historical stock prices Current Share Price ₹1,378.25 52 Week High ₹1,593.00 52 Week Low ₹810.10 Beta 0.32 1 Month Change 0.15% 3 Month Change 4.06% 1 Year Change 55.69% 3 Year Change 100.41% 5 Year Change 205.50% Change since IPO 129.31%
Recent News & Updates
Now 22% overvalued after recent price rise Nov 03
New minor risk - Profit margin trend Oct 26
Second quarter 2025 earnings: EPS misses analyst expectations Oct 26
Eris Lifesciences Limited to Report Q2, 2025 Results on Oct 25, 2024 Oct 22
Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of Chemman Labs Private Limited. Oct 15
Price target increased by 7.3% to ₹1,334 Sep 13 See more updates
Now 22% overvalued after recent price rise Nov 03
New minor risk - Profit margin trend Oct 26
Second quarter 2025 earnings: EPS misses analyst expectations Oct 26
Eris Lifesciences Limited to Report Q2, 2025 Results on Oct 25, 2024 Oct 22
Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of Chemman Labs Private Limited. Oct 15
Price target increased by 7.3% to ₹1,334 Sep 13
Price target increased by 12% to ₹1,243 Aug 05
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 03
Eris Lifesciences Limited, Annual General Meeting, Sep 25, 2024 Aug 02
Eris Lifesciences Limited to Report Q1, 2025 Results on Aug 02, 2024 Jul 30
Now 2.1% overvalued after recent price rise Jul 05
Now 3.9% overvalued after recent price rise Jul 05
Now 3.9% overvalued after recent price rise Jul 05
Now 20% overvalued after recent price rise Jun 18
Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel. Jun 13
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 22
Eris Lifesciences Limited to Report Q4, 2024 Results on May 21, 2024 May 16
Now 21% undervalued after recent price drop Feb 27
Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of 51% stake in Swiss Parenterals Limited. Feb 16
Eris Lifesciences Limited (NSEI:ERIS) agreed to acquire 51% stake in Swiss Parenterals Limited INR6.4 billion. Feb 15
Third quarter 2024 earnings released: EPS: ₹7.55 (vs ₹7.49 in 3Q 2023) Feb 14
Eris Lifesciences Limited to Report Q3, 2024 Results on Feb 13, 2024 Feb 07
Insufficient new directors Feb 01
Now 22% overvalued after recent price rise Jan 24
Eris Lifesciences Limited (NSEI:ERIS) entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion. Nov 10
Second quarter 2024 earnings: EPS exceeds analyst expectations Nov 09
Eris Lifesciences Limited to Report Q2, 2024 Results on Nov 08, 2023 Nov 02
Insider recently sold ₹1.6m worth of stock Aug 20
New major risk - Dividend sustainability Aug 08
Eris Lifesciences Limited, Annual General Meeting, Sep 25, 2023 Aug 08
First quarter 2024 earnings released: EPS: ₹6.97 (vs ₹6.96 in 1Q 2023) Aug 08
Eris Lifesciences Limited to Report Q1, 2024 Results on Aug 07, 2023 Aug 01
Full year 2023 earnings: EPS misses analyst expectations May 18
Eris Lifesciences Limited to Report Q4, 2023 Results on May 17, 2023 May 11
Chairman & MD recently bought ₹7.2m worth of stock Feb 08
Chairman & MD recently bought ₹128m worth of stock Jan 25
Eris Lifesciences Limited (NSEI:ERIS) acquired dermatology portfolio of Glenmark Pharmaceuticals Limited from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for Rs 3.4 billion. Jan 18
Third quarter 2023 earnings released: EPS: ₹7.49 (vs ₹7.41 in 3Q 2022) Jan 18
Eris Lifesciences Limited to Report Q3, 2023 Results on Jan 17, 2023 Jan 11
Chairman & MD recently bought ₹109m worth of stock Dec 10
High number of new directors Nov 16
Second quarter 2023 earnings released: EPS: ₹8.84 (vs ₹8.71 in 2Q 2022) Oct 21
Consensus forecasts updated Oct 21
Eris Lifesciences Limited to Report First Half, 2023 Results on Oct 20, 2022 Oct 12
Now 20% undervalued Oct 10
Insider recently sold ₹2.4m worth of stock Sep 23
First quarter 2023 earnings released: EPS: ₹6.96 (vs ₹7.86 in 1Q 2022) Aug 07
Eris Lifesciences Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on or Before 04 September 2022 Aug 05
Eris Lifesciences Limited to Report Q1, 2023 Results on Aug 05, 2022 Jul 30
Less than half of directors are independent Jul 21
Eris Lifesciences Limited Announces Resignation of Vijaya Sampath as Independent Director Jul 20
Eris Lifesciences Limited, Annual General Meeting, Sep 01, 2022 Jun 16
Insider recently sold ₹2.1m worth of stock May 25
Consensus forecasts updated May 10
Eris Lifesciences Limited (BSE:540596) agreed to acquire Oaknet Healthcare Private Limited for INR 6.5 billion. May 04
Full year 2022 earnings: Revenues and EPS in line with analyst expectations May 04
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Jan 30
Insider recently sold ₹1.7m worth of stock Nov 09
Second quarter 2022 earnings released: EPS ₹8.71 (vs ₹7.93 in 2Q 2021) Oct 30
Insider recently sold ₹678k worth of stock Sep 16
Chairman & MD recently bought ₹19m worth of stock Aug 21
Insider recently sold ₹8.0m worth of stock Aug 05
Price target increased to ₹810 Jul 30
First quarter 2022 earnings released: EPS ₹7.86 (vs ₹6.56 in 1Q 2021) Jul 30
Insider recently sold ₹186m worth of stock May 27
Full year 2021 earnings released: EPS ₹26.16 (vs ₹21.61 in FY 2020) May 14
Insider recently sold ₹10m worth of stock Apr 04
Price target raised to ₹721 Feb 02
Third quarter 2021 earnings released: EPS ₹6.64 (vs ₹4.62 in 3Q 2020) Jan 30
Revenue beats expectations Jan 30
Eris Lifesciences Limited to Report Q3, 2021 Results on Jan 28, 2021 Jan 21
New 90-day high: ₹598 Jan 06
Eris Lifesciences Limited Appoints Krishnakumar Vaidyanathan as an Additional Director Executive Dec 23
New 90-day high: ₹550 Dec 16
Revenue and earnings beat expectations Nov 04
Second quarter 2021 earnings released: EPS ₹7.93 Nov 04
Eris Lifesciences Limited to Report Q2, 2021 Results on Nov 03, 2020 Oct 28
Insider recently sold ₹968m worth of stock Oct 04
Price target raised to ₹624 Aug 11
First quarter earnings released Aug 05
New 90-day high - ₹540 Aug 03 Shareholder Returns 540596 IN Pharmaceuticals IN Market 7D -6.1% 0.8% -4.2% 1Y 55.7% 39.7% 19.1%
See full shareholder returns
Return vs Market: 540596 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility Is 540596's price volatile compared to industry and market? 540596 volatility 540596 Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 540596 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 540596's weekly volatility (5%) has been stable over the past year.
About the Company Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions.
Show more Eris Lifesciences Limited Fundamentals Summary How do Eris Lifesciences's earnings and revenue compare to its market cap? 540596 fundamental statistics Market cap ₹187.87b Earnings (TTM ) ₹3.48b Revenue (TTM ) ₹24.85b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 540596 income statement (TTM ) Revenue ₹24.85b Cost of Revenue ₹5.90b Gross Profit ₹18.95b Other Expenses ₹15.47b Earnings ₹3.48b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 25.60 Gross Margin 76.25% Net Profit Margin 14.02% Debt/Equity Ratio 84.8%
How did 540596 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 21:27 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Eris Lifesciences Limited is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Prashant Nair Ambit Capital Nitin Bhasin Ambit Capital Harith Ahamed Avendus Spark
Show 14 more analysts 
